Clinical Trial Update: Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy [Phase 2]

View source ↗

Summary

This release provides results from a Phase 2 trial of a personalized immunotherapy for patients with recurrent or metastatic head and neck squamous cell carcino…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Personalized immunotherapy

Snippet

Sponsor: Dan Zandberg | Conditions: Squamous Cell Carcinoma of the Head and Neck | Phase 2 | Status: COMPLETED | Results posted: 2026-01-08